P. Jeffrey Conn

February 6, 2020

Conn, Calipari to receive major pharmacology awards

Two Vanderbilt University pharmacologists have won prestigious awards from the American Society for Pharmacology and Experimental Therapeutics (ASPET).

By Bill Snyder
Max Joffe, PhD, left, P. Jeffrey Conn, PhD, and colleagues are studying a new class of antidepressants that may relieve symptoms more rapidly and with fewer side effects.
November 21, 2019

Study explores potential new class of antidepressants

Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.

By Bill Snyder
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer’s disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

By Craig Boerner
microscope
August 15, 2016

Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

By Bill Snyder
July 16, 2015

Grant enhances mental illness drug research efforts

Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.

By Bill Snyder